BetterInvesting Magazine Update on The Walt Disney Co.

BetterInvesting Magazine Update on The Walt Disney Co.

Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.

The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

The fundamental data is eye-opening; investors can view Disney's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?studyid=16958122 .

A full report on Disney will appear in the August 2025 issue of BetterInvesting Magazine.

The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc.  (AMGN: NASDAQ), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective.

Committee members are Daniel J. Boyle , CFA; Marisa Bradbury , CFA; Philip Keating , CFA; Walter J. Kirchberger , CFA; Anne Nichols , CFA; and Dan Rutter , CFA.

Doron P. Levin , an editor of the magazine, serves as the committee's chairperson.

Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn , Instagram and Facebook .

Contact: 877-275-6242

Cision View original content: https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-the-walt-disney-co-nyse-dis-302474596.html

SOURCE NAIC-BetterInvesting

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Transparent blue cells with dark centers floating against a vibrant blue background.

Biotech and Pharma Market Update: Q1 2026 in Review

The life science sector began the year on a constructive note, after a strong performance toward the end of 2025, but signals in Q1 point to a market continuing to reward proof over promise. A recent interview with Eric Shrayer, director of research at Reynders and McVeigh Capital Management,... Keep Reading...
A glass flask on a reflective table with overlaid stock market charts and numerical data, including text reading: 0.00%.

Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio

AI developer Anthropic is acquiring New York-based biotech startup Coefficient Bio for approximately US$400 million, according to The Information.Founded just last fall and operating largely in stealth, Coefficient Bio will be absorbed directly into Anthropic’s healthcare life sciences... Keep Reading...
Lexaria Applauds Eli Lilly's Foundayo Drug Approval

Lexaria Applauds Eli Lilly's Foundayo Drug Approval

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...
Lexaria Applauds Eli Lilly's Foundayo Drug Approval

Lexaria Applauds Eli Lilly's Foundayo Drug Approval

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate at the upcoming TD Cowen... Keep Reading...
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...

Interactive Chart

Latest Press Releases

Related News